Medigen Biotechnology (3176) Monthly Revenue

Market: TPEx (OTC) · Industry: Biotech & Medical · 基亞

Medigen Biotechnology (3176) reported revenue of NT$151.5 million for Oct 2026, +6.6% year on year and -40.6% from the previous month. Revenue for Jan–Oct 2026 was NT$1.38 billion (-1.4% year on year).

Year-on-year revenue growth: 3 months in a row. →

In Oct 2026, it ranked No. 55 by revenue among 160 Biotech & Medical companies.

Monthly revenue chart

Oct 2024 NT$115.7 million24/10Nov 2024 NT$108.7 millionDec 2024 NT$106.3 millionJan 2025 NT$97.3 millionFeb 2025 NT$89.1 million25/02Mar 2025 NT$313 millionApr 2025 NT$105.2 millionMay 2025 NT$119.1 millionJun 2025 NT$135.5 million25/06Jul 2025 NT$115.4 millionAug 2025 NT$110.7 millionSep 2025 NT$170.6 millionOct 2025 NT$142.1 million25/10Nov 2025 NT$90 millionDec 2025 NT$94.5 millionJan 2026 NT$93.3 millionFeb 2026 NT$67.7 million26/02Mar 2026 NT$100.5 millionApr 2026 NT$94.4 millionMay 2026 NT$95.5 millionJun 2026 NT$94.8 million26/06Jul 2026 NT$96.4 millionAug 2026 NT$329.2 millionSep 2026 NT$255.2 millionOct 2026 NT$151.5 million26/10

Hover over (or tap) a bar to see that month’s revenue.

Monthly revenue history

MonthRevenueYoYMoM
Oct 2026NT$151.5 million+6.6%-40.6%
Sep 2026NT$255.2 million+49.6%-22.5%
Aug 2026NT$329.2 million+197.4%+241.4%
Jul 2026NT$96.4 million-16.4%+1.7%
Jun 2026NT$94.8 million-30.0%-0.7%
May 2026NT$95.5 million-19.8%+1.2%
Apr 2026NT$94.4 million-10.3%-6.1%
Mar 2026NT$100.5 million-67.9%+48.4%
Feb 2026NT$67.7 million-24.0%-27.4%
Jan 2026NT$93.3 million-4.0%-1.3%
Dec 2025NT$94.5 million-11.1%+5.0%
Nov 2025NT$90 million-17.2%-36.7%
Oct 2025NT$142.1 million+22.9%-16.7%
Sep 2025NT$170.6 million-14.4%+54.1%
Aug 2025NT$110.7 million-2.8%-4.1%
Jul 2025NT$115.4 million-6.6%-14.9%
Jun 2025NT$135.5 million+21.8%+13.8%
May 2025NT$119.1 million-16.2%+13.2%
Apr 2025NT$105.2 million+4.4%-66.4%
Mar 2025NT$313 million+203.0%+251.3%
Feb 2025NT$89.1 million+27.9%-8.4%
Jan 2025NT$97.3 million+24.2%-8.5%
Dec 2024NT$106.3 million+21.7%-2.3%
Nov 2024NT$108.7 million-14.7%-6.0%
Oct 2024NT$115.7 million-26.0%-41.9%

Jan–Oct 2026 cumulative: NT$1.38 billion (-1.4% YoY)

History covers months since this site began collecting, plus prior-month and prior-year figures in each release. It grows every month.

Other Biotech & Medical companies

Compare with peers: Medigen Biotechnology vs PEC / Medigen Biotechnology vs Lotus Pharm / Medigen Biotechnology vs Bora

CompanyRevenueYoY
PEC6446NT$2.84 billion+102.0%
Lotus Pharm1795NT$2.13 billion-22.5%
Bora6472NT$1.99 billion+15.9%
Great Tree Pharmacy6469NT$1.67 billion+1.5%
EXCELSIOR4104NT$1.02 billion+38.6%
PEGAVISION6491NT$793 million+13.0%
Synmosa Biopharma4114NT$766.6 million+41.2%
Y.S.H.3705NT$749.4 million+4.4%

See also

← All Taiwan listed & OTC companies

Sources: Taiwan Stock Exchange, monthly revenue of listed companies (Government Open Data Platform); Taipei Exchange, monthly revenue of OTC companies (TPEx OpenAPI); historical months from MOPS. Amounts in New Taiwan dollars. Changes calculated by this site from the source figures. Not investment advice. Updated: 2026-11-16